Denosumab may play a central role in the treatment of diffuse sclerosing osteomyelitis of the mandible. This report describes two patients who had been treated unsuccessfully with antibiotics and steroids for several years. After denosumab treatment, both patients became pain‐free and the radiological examination showed less severe osteomyelitis
Osteonecrosis of the jaws is a complication after treatment with antiresorptive drugs. Bisphosphonat...
Denosumab has been suggested as a first-line therapy for osteoporotic patients. However, a standardi...
Osteonecrosis of the jaw (ONJ) is a serious adverse event of bone resorption inhibitors (BRIs), such...
Key Clinical Message Denosumab may play a central role in the treatment of diffuse sclerosing osteom...
Diffuse sclerosing osteomyelitis of the jaw (DSO) is a rare and poorly understood disease. Nowadays ...
Treating chronic diffuse sclerosing osteomyelitis (DSO) is challenging and many treatments have been...
Denosumab has proved effective at low doses in increasing bone mineral density in osteoporosis patie...
This study aims to evaluate short-term and long-term results of bisphosphonate therapy in patients w...
Denosumab has proved effective at low doses in increasing bone mineral density in osteoporosis patie...
Denosumab, a human monoclonal antibody directed against the receptor activator of nuclear factor-κ β...
Denosumab, a monoclonal antibody against the receptor activator for nuclear factor-kappa B ligand (R...
Diffuse sclerosing osteomyelitis of the mandible is a disease that is characterized by a protracted ...
Introduction: Medication-related osteonecrosis of the jaw (MRONJ) is a severely debilitating conditi...
Background: This case report shows an affected postmenopausal patient with medicaments related osteo...
We present three clinical cases of successful osteoporosis treatment with denosumab in patients with...
Osteonecrosis of the jaws is a complication after treatment with antiresorptive drugs. Bisphosphonat...
Denosumab has been suggested as a first-line therapy for osteoporotic patients. However, a standardi...
Osteonecrosis of the jaw (ONJ) is a serious adverse event of bone resorption inhibitors (BRIs), such...
Key Clinical Message Denosumab may play a central role in the treatment of diffuse sclerosing osteom...
Diffuse sclerosing osteomyelitis of the jaw (DSO) is a rare and poorly understood disease. Nowadays ...
Treating chronic diffuse sclerosing osteomyelitis (DSO) is challenging and many treatments have been...
Denosumab has proved effective at low doses in increasing bone mineral density in osteoporosis patie...
This study aims to evaluate short-term and long-term results of bisphosphonate therapy in patients w...
Denosumab has proved effective at low doses in increasing bone mineral density in osteoporosis patie...
Denosumab, a human monoclonal antibody directed against the receptor activator of nuclear factor-κ β...
Denosumab, a monoclonal antibody against the receptor activator for nuclear factor-kappa B ligand (R...
Diffuse sclerosing osteomyelitis of the mandible is a disease that is characterized by a protracted ...
Introduction: Medication-related osteonecrosis of the jaw (MRONJ) is a severely debilitating conditi...
Background: This case report shows an affected postmenopausal patient with medicaments related osteo...
We present three clinical cases of successful osteoporosis treatment with denosumab in patients with...
Osteonecrosis of the jaws is a complication after treatment with antiresorptive drugs. Bisphosphonat...
Denosumab has been suggested as a first-line therapy for osteoporotic patients. However, a standardi...
Osteonecrosis of the jaw (ONJ) is a serious adverse event of bone resorption inhibitors (BRIs), such...